Vaccination boosted immunity acquired from previous SARS-CoV-2 infection
1. Two doses of the Pfizer-BioNTech BNT162b2 vaccine were linked to high immediate protection again severe acute respiratory syndrome coronary ...
Tag: sars-cov-2 variants
Covid-19 vaccines and boosters are transiently effective against the Omicron
1. Two doses of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccine provided good protection against the Omicron (B.1.1.529) variant but rapidly ...
Widespread population immunity of Covid-19 observed in South Africa before Omicron wave
1. Widespread underlying SARS-CoV-2 seropositivity was observed in Gauteng province, South Africa, before the omicron wave. 2. Epidemiologic data demonstrated ...
Rapid antigen tests detect high SARS-CoV-2 levels during the Omicron surge
1. Rapid antigen tests detected persons with high SARS-CoV-2 levels, enabling rapid response to positive test results. 2. Repeated testing ...
mRNA vaccine boosters less effective against the omicron variant in Qatar
1. mRNA booster vaccines for Covid-19 were highly effective against delta infection but less effective against omicron infection. 2. mRNA ...
BNT162b2 COVID-19 vaccine may reduce hospitalizations from SARS-CoV-2 delta variant for up to six months
1. Despite waning effectiveness against SARS-CoV-2 infection, fully vaccinated patients continued to show low COVID-19 hospitalization rates up to 5 ...
Nationwide vaccination campaign with BNT162b2 (Pfizer–BioNTech) mRNA vaccine reports high immunogenicity across all age groups
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their ...
Prior SARS-CoV-2 infection is associated with protection against reinfection
1. Previous infection from SARS-CoV-2 was linked to an 84% lower incidence of reinfection. 2. Median interval between primary infection ...
ChAdOx1 nCoV-19 (AstraZeneca) vaccine is effective against the SARS-CoV-2 B.1.1.7 variant
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The ...